 Data from the HSP-130 6 mg regimen plus 3 mg, as appropriate will be analysed, discussed with the FDA and determination if a dose greater than 6 mg is appropriate to study e.g., 12 mg. If all three doses are studied, a total enrollment of up to 36 subjects is projected for Cycles 1-4. 